Golar LNG Limited (“Golar” or “the Company”) reports Q4 2025 net income attributable to Golar of $10 million inclusive of $28 million of non-cash items 1, Adjusted EBITDA 1 of $91 million and Total ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results and provided key updates for the fourth quarter and year ended December 31, 2025.
45m
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results